A new review published in the Journal of Law, Medicine & Ethics documents what anyone paying attention already suspected: every major pharmaceutical company has been implicated in systematic bribery schemes targeting FDA advisory panel members, medical textbook authors, clinical trial designers, and patient advocacy groups.
Pfizer. Johnson & Johnson. AstraZeneca. GlaxoSmithKline. Eli Lilly. The report draws on decades of OECD investigations and enforcement actions to build a picture of an industry that does not occasionally bend the rules but has built its business model around corrupting the people meant to regulate it.
The corruption is structural. FDA advisory panels vote on whether drugs reach the market. The companies whose drugs are being evaluated pay consulting fees to the people casting those votes. Clinical trials meant to test whether a drug works are designed by researchers who receive funding from the company that makes the drug. Patient advocacy groups that lobby for faster approvals are funded by the companies seeking those approvals.
The report has received coverage in exactly one category of media: academic journals and independent health outlets. Not a single major network has touched it. Not CNN. Not the New York Times. Not the Washington Post.
The silence is not coincidental. Pharmaceutical companies are among the largest advertisers in American media. The networks that would need to report on pharma corruption are funded by pharma advertising. The conflict of interest is not hidden – it runs during every commercial break.
When the companies that make the drugs, fund the research, pay the regulators, sponsor the advocacy groups, and advertise on the networks are all the same companies – where exactly is the independent check supposed to come from?
